Which of the following antiretroviral therapy is contraindicated in pregnancy
The core concept here is understanding the safety profiles of antiretrovirals in pregnant patients. The key is knowing which drugs are not recommended due to teratogenic effects or other maternal-fetal risks.
The correct answer is probably one of the options that's known for causing birth defects. Let me think: Dolutegravir has been associated with neural tube defects when taken during the first trimester. So if that's one of the options, that's the right answer.
Now, the incorrect options might include drugs that are actually safe. For example, Tenofovir is commonly used in pregnancy. Efavirenz might be avoided in the first trimester but isn't contraindicated. Nucleoside reverse transcriptase inhibitors like Zidovudine are standard in pregnancy. So the wrong options would be other ARVs that are considered safe or have warnings but aren't absolute contraindications.
The clinical pearl here is remembering that Dolutegravir is contraindicated in the first trimester due to neural tube defects, and alternatives like Raltegravir are preferred. Also, Efavirenz is not contraindicated but is avoided in early pregnancy.
I need to structure the explanation with all the required sections, making sure each part is concise and accurate. Let me check again: Core Concept, why correct answer is right (mechanism), why others are wrong, clinical pearl, then the correct answer line. Keep it under 2500 characters. Avoid markdown except for the specified sections. Use bold for section headers. Make sure each wrong option is addressed properly. Alright, time to put it all together.
**Core Concept**
Antiretroviral therapy (ART) during pregnancy requires balancing maternal HIV suppression with fetal safety. **Dolutegravir**, an integrase inhibitor, is contraindicated in the first trimester due to teratogenic risks, particularly neural tube defects.
**Why the Correct Answer is Right**
**Dolutegravir** is contraindicated in early pregnancy because of its association with neural tube defects (e.g., anencephaly) when used in the first trimester. This risk is most pronounced in the first 12 weeks of gestation. The U.S. FDA and WHO recommend avoiding dolutegravir unless no alternatives exist, emphasizing its teratogenic potential over its virologic efficacy.
**Why Each Wrong Option is Incorrect**
**Option A:** *Tenofovir disoproxil fumarate (TDF)* is safe in pregnancy and a first-line ART agent. It does not increase fetal abnormalities.
**Option B:** *Efavirenz* is not contraindicated but is avoided in the first trimester due to theoretical teratogenicity; it is not absolutely contraindicated.
**Option C:** *Zidovudine* is pregnancy category B and a cornerstone of intrapartum ART to prevent mother-to-child transmission.
**Clinical Pearl / High-Yield Fact**
**Dolutegravir = Neural tube defect